Stockreport

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients [Yahoo! Finance]

Acurx Pharmaceuticals, Inc.  (ACXP) 
PDF Ibezapolstat, but not vancomycin, consistently preserved and allowed regrowth of key gut bacterial species believed to confer health benefits including to prevent recur [Read more]